Viking Therapeutics (VKTX) is scheduled to report fourth-quarter 2018 financial results on March 13, Wednesday, after the regular trading hours. The market expects the company to report a loss of 10 cents per share during the quarter, narrower than the 14 cents per share loss it reported in the same period last year.
During the year-over quarter, net loss had increased by 14%, hurt by higher research and development expenses. As we head into the fourth quarter of this year, the clinical-stage biopharmaceutical firm is expected to see further growth in R&D expenses, which in turn, would weigh on results.
VKTX shares have gained 30% in the trailing 52 weeks. However, it has declined 60% since hitting a record peak in September last year.
Investors will be looking forward to any updates regarding the ongoing research on nonalcoholic steatohepatitis (NASH), a liver disease. Last month, Viking shares had jumped 6% after it was reported that rival Gilead Sciences’ (GILD) NASH candidate failed to meet its primary endpoint.
The stock once again received a bump when peer firm Intercept Pharmaceuticals (ICPT) produced positive topline results from the phase 3 study for its NASH drug. According to DelveInsight, the NASH market will experience significant annual growth over the 2016-2028 study period, as major-market sales increase up to $30.1 billion by 2028.
The stock has a 12-month average price target of $23, which represents a 193% upside from the last close. Hence the scope for a rally is high if the California-based firm pleases investors.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,